Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients

Nephrology

Volumn 13, Issue 4, 2008, Pages 284-288

  Beavers, Kristen M ^a   Beavers, Daniel P ^a   Bowden, Rodney G ^a   Wilson, Ronald L ^b   Gentile, Mindy ^c  

^a BAYLOR UNIVERSITY   (United States)

^b Central Texas Nephrology Associates   (United States)

^c Brazos Kidney Center   (United States)

Author keywords

End stage renal disease; Fish oil; Homocysteine; Omega 3 fatty acid

Indexed keywords

CORN OIL; DOCOSAHEXAENOIC ACID; FISH OIL; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CORN OIL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUGS, NON-PRESCRIPTION; EICOSAPENTAENOIC ACID; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TEXAS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 43449136454     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00934.x     Document Type: Article

References (23)

1. Locatelli F, Marcelli D, Conte F et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J. Am. Soc. Nephrol. 2001 12 : 2411 17.
2. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am. J.Clin. Nutr. 2000 72 : 324 32.
3. Lentz S. Homocysteine and cardiovascular physiology. In : Carmel R, Jacobsen DW (eds). Homocysteine in Health and Disease. New York : Cambridge University Press, 2001 441 50.
4. Stam F, van Guldener C, Ter Wee PM, Jakobs C, de Meer K, Stehouwer CD. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int. 2005 67 : 259 64.
5. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron. Artery Dis. 1993 4 : 53 60.
6. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: A critical review. J. Lipid Res. 1989 30 : 785 807.
7. von Schacky C. n-3 fatty acids and the prevention of coronary atherosclerosis. Am. J. Clin. Nutr. 2000 71 (Suppl. 1 224S 7S.
8. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am. J. Clin. Nutr. 2000 71 (Suppl. 1 202S 7S.
9. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J. Am. Coll. Cardiol. 2000 35 : 265 70.
10. Piolot A, Blache D, Boulet L et al. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J. Lab. Clin. Med. 2003 141 : 41 9.
11. Fiedler R, Mall M, Wand C, Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J. Ren. Nutr. 2005 15 : 253 6.
12. Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J. Nutr. Biochem. 2006 17 : 379 84.
13. Fontani G, Corradeschi F, Felici A et al. Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with Omega-3 polyunsaturated fatty acids. Eur. J. Clin. Invest. 2005 35 : 499 507.
14. de Bree A, Mennen LI, Hercberg S, Galan P. Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. Eur. J. Clin. Nutr. 2004 58 : 732 44.
15. Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J. Nutr. 2005 135 : 1093 101.
16. Lee J, Kusek J, Greene P et al. Assessing medication adherence by pill count and electronic monitoring in the African American study of kidney disease and hypertension (AASK) pilot study. Am. J. Hypertens. 1996 9 : 719 25.
17. Holdt B, Korten G, Knippel M et al. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit. Dial. Int. 1996 16 (Suppl. 1 S246 9.
18. Cramp DG, Moorhead JF, Wills MR. Disorders of blood-lipids in renal disease. Lancet 1975 1 : 672 3.
19. Marouf R, Zubaid M, Mojiminiyi OA et al. Determinants of plasma homocysteine in relation to hematological and biochemical variables in patients with acute myocardial infarction. South. Med. J. 2006 99 : 811 16.
20. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin. Thromb. Hemost. 2000 26 : 263 79.
21. Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M. Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren. Fail. 2004 26 : 709 14.
22. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic. Biol. Med. 1993 14 : 683 93.
23. Baro L, Fonolla J, Pena JL et al. n-3 fatty acids plus oleic acid and vitamin supplemented milk consumption reduces total and LDL cholesterol, homocysteine and levels of endothelial adhesion molecules in healthy humans. Clin. Nutr. 2003 22 : 175 82.